Delivering new horizons for heart health

Esperion is a pharmaceutical company focused on developing and commercializing first-in-class, oral,
low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with
elevated LDL-C.

Many patients with elevated LDL-C have LDL-C levels not adequately controlled with current lipid-modifying therapies. Patients with elevated LDL-C only able to tolerate less than the lowest approved daily starting dose of a statin can be considered having “statin intolerance“. Our lead product candidate, bempedoic acid (ETC-1002), is a first-in-class, orally available, small molecule designed to significantly lower elevated levels of LDL-C — with reduced potential for muscle-related side effects associated with statin use.

Clinical Studies

Esperion launched its global pivotal Phase 3 program, Cholesterol Lowering via BEmpedoic Acid, an ACL-inhibiting Regimen (CLEAR), with the initiation of CLEAR Harmony (1002-040). a long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia. Learn more about our planned clinical studies and results.


Meet Esperion

Our founder and chief scientific officer, Roger Newton, co-discovered the statin marketed as Lipitor® (atorvastatin) — the most commonly prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history. Learn more about our management team’s track record of success.


Statin Intolerance

It is estimated that approximately 10% of patients prescribed statins, 8 million patients in the U.S., Europe and Japan, are considered “statin intolerant”.